SUMMARY OF PRODUCT CHARACTERISTICS
|
|
- Christine Strickland
- 5 years ago
- Views:
Transcription
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tiaprid XXX 100 mg, tablets 2. QUALITATIVE AND QUANTIATIVE COMPOSITION Each tablet contains 100 mg tiapride (as hydrochloride). For the full list of excipients, see section PHARMACEUTICAL FORM Tablet White, round tablets with beveled edge and a cross on both sides. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications For the treatment of neuroleptic-induced tardive dyskinesia, mainly oro-bucco-lingual type. 4.2 Posology and method of administration Adults should take mg tiapride three times daily, depending on the severity of the disease and the body weight of the individual. The proposed daily dose for the claimed indication is mg tiapride. The effect of treatment may not be apparent until after a period of 4-6 weeks of treatment. Tiaprid XXX tablets should preferably be taken with a little liquid after meals. Tiapride is not intended for treatment in children. Dosage in renal impairment Creatinine clearance: ml/min = 75 % of the ml/min = 50 % normal less than 10 ml/min = 25 % daily dose 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Concomitant Prolactin-dependent tumours, e.g. pituitary gland prolactinoma and breast cancer. 1
2 Phaeochromocytoma. Association with levodopa or other dopaminergic medicines (see section 4.5). Neuroleptic malignant syndrome (see section 4.8). 4.4 Special warnings and precautions for use As with other neuroleptics, Neuroleptic Malignant Syndrome, a potentially fatal complication, which is characterised by hyperthermia, muscle rigidity and autonomic dysfunction may occur. In case of hyperthermia of undiagnosed origin, tiapride should be discontinued. Neuroleptic agents may reduce the seizure threshold in epilepsy, although this has not been evaluated with tiapride. Therefore, patients with a history of epilepsy should be closely monitored during tiapride treatment. In patients with renal impairment the dose has to be reduced, while in patients with severely impaired renal function tiapride should be discontinued on medical advice (see section 4.2). Tiapride should not be used in patients with Parkinson s disease, with the exception of special circumstances. Because tiapride can have an increased sedative effect in elderly patients, caution should be exercised. New researches indicate that increased prolactine levels may be associated with an increased risk of breast cancer. Notwithstanding, due to a lack of epidemiologic studies, a final conclusion on hyperprolactinemia as an independent risk factor of breast cancer can so far not be drawn. Prolongation of the QT interval Tiapride may induce a prolongation of the QT interval. This effect is known to potentiate the risk of serious ventricular arrhythmias such as torsades de pointes (see section 4.8). Before any administration, and if possible according to the patient s clinical status, it is recommended to monitor factors which could favour the occurrence of this rhythm disorder, such as for example: - bradycardia less than 55 bpm, - electrolyte imbalance in particular hypokalaemia, - congenital prolongation of the QT interval, - on-going treatment with a medication likely to produce pronounced bradycardia (< 55 bpm), electrolyte imbalance, decreased intracardiac conduction, or prolongation of the QT interval (see section 4.5). Tiapride should be prescribed with caution in patients presenting with risk factors which may predispose to prolongation of the QT interval. Venous thromboembolism Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with tiapride and preventive measures undertaken. Increased Mortality in Elderly people with dementia Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drugtreated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was 2
3 about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Tiapride is not licensed for the treatment of dementia-related behavioural disturbances. Stroke In randomized clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs or other populations of patients cannot be excluded. Tiapride should be used with caution in patients with stroke risk factors. Children In children, tiapride has not been thoroughly investigated. Therefore, tiapirde is not intended for treatment in children (see section 4.2). 4.5 Interactions with other medicinal products and other forms of interaction Combinations which are contraindicated Dopaminergic agonists, excluding patients with Parkinson s disease (cabergoline, quinagolide), due to reciprocal antagonism between dopaminergic agonists and neuroleptics. Combinations which are not recommended Medications which can induce torsades de pointes Class Ia (quinidine, hydroquinidine, disopyramide), and class III antiarrhythmic agents (amiodarone, sotalol, dofetilide, ibutilide), certain neuroleptics (sultopride, pipothiazine, sertindole, veralipide, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, pimozide, haloperidol, droperidol, fluphenazine, pipamperone, flupentixol, zuclopentixol), some antiparasitic drugs (halofantrine, lumefrantine, pentamidine), other medications: IV erythromycin, IV spiramycin, moxifloxacin, bepridil, cisapride, diphemanil, mizolastine, IV vincamine. Increased risk of ventricular arrhythmias, especially torsades de pointes. If possible, discontinue the medication that can induce torsades de pointes, except for antiinfective agents. If combination therapy cannot be avoided, check the QT interval before starting treatment and monitor ECG. Alcohol Alcohol may enhance the sedative effect of neuroleptics. The alteration of the vigilance can make dangerous the driving of vehicles and the use of machines. Avoid drinking alcohol and taking medicines containing alcohol. Levodopa Reciprocal antagonism of the effects of levodopa and neuroleptics. Use minimal effective doses of each of both drugs in patients with Parkinson s disease. Dopaminergic agonists except levodopa 3
4 Amantadine, apomorphine, bromocriptine, entacapone, lisuride, pergolide, piribedil, pramipexole, ropinirole, selegiline in patients with Parkinson s disease. Reciprocal antagonism of the effects of the dopaminergic agonist and neuroleptics. The dopaminergic agonist can induce or accentuate psychotic disorders. When neuroleptic therapy cannot be avoided in patients with Parkinson s disease treated with dopaminergic agonists, these agents must be tapered off and discontinued (sudden withdrawal of dopaminergic agonists can induce neuroleptic malignant syndrome). Methadone Enhanced risk of ventricular arrhythmia, in particular torsades de pointes. Combinations which require precautions for use Bradycardia-inducing agents In particular class Ia antiarrhythmia agents, beta-blockers, some class II antiarrhythmia agents, some calcium antagonists, cardiac glycosides, pilocarpine, cholinesterase-inhibitors: increased risk of ventricular arrhythmias, especially torsades de pointes. Clinical and electrocardiographic monitoring. Beta-blockers in heart failure Bisoprolol, carvedilol, metoprolol, nebivolol. Enhanced risk of ventricular arrhythmia, inparticular torsades de pointes. Clinical monitoring and ECG monitoring are necessary. Potassium-lowering agents Potassium-lowering diuretics, stimulant laxatives, IV amphotericin B, glucocorticoids, cosyntropin. Increased risk of ventricular arrhythmias, especially torsades de pointes. Correct any hypokalaemia before starting treatment with amisulpride and ensure clinical, electrolyte and electrocardiographic monitoring. Its concomitant administration has to be taken into account Antihypertensives (all) Antihypertensive effect and increased risk of orthostatic hypotension (additive effect). Other central nervous system depressants Narcotics (analgesics, antitussives and opioid replacement therapy); barbiturates; benzodiazepines; other non-benzodiazepine anxiolytics; hypnotics; neuroleptics; sedative antidepressants (amitriptyline, doxepine, mianserin, mirtazapine, trimipramine); sedative H1 antihistamines; centrally-acting antihypertensives; other drugs: baclofen, thalidomide, pizotifene. Increase of central depression. Impaired alertness may make the driving of vehicles and the use of machines dangerous. Beta-blockers (except esmolol, sotalol and beta-blockers used in heart failure) Vasodilatator effect and risk of hypotension, in particular postural hypotension (additive effect). Nitrate derivatives and related compounds Anticholinergics such as biperiden can attenuate the action of tiapride. 4.6 Fertility, pregnancy and lactation 4
5 Pregnancy If drug therapy is needed to maintain a good mental balance and to avoid decompensation, it must be instituted or continued at effective dose throughout the pregnancy. There are limited amount of data from the use of tiapride in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Injectable neuroleptics used in emergency situations can cause maternal hypotension. In neonates born to mothers receiving prolonged high-dose neuroleptic treatment, extrapyramidal syndromes (hypertonia, tremor) have been described in rare cases. Neonates exposed to antipsychotics (including tiapride) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully. Breastfeeding It is not known whether tiapride is excreted in breast milk. Breast-feeding during treatment with tiapride is not recommended. Fertility A decrease in fertility was observed in animals treated with tiapride. In humans, because of the interaction with dopamine receptors, tiapride may cause hyperprolactinemia which can be associated with amenorrhea, anovulation, and impaired fertility (see section 4.8). 4.7 Effect on ability to drive and use machines Even when used as recommended, tiapride may cause sedation so that the ability to drive vehicles or operate machinery can be impaired (see section 4.8). 4.8 Undesirable effects Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Undesirable effects are indicated in accordance with the following incidences: very common ( 1/10), common ( 1/100 to <1/10), uncommon ( 1/1,000 to <1/100), rare ( 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). Data of clinical studies During controlled clinical studies the following adverse effects were reported. It should be noted that in some instances it can be difficult to differentiate adverse events from symptoms of the underlying disease. Endocrine disorders Common: hyperprolactinemia* * Hyperprolactinemia may in some cases induce galactorrhea, amenorrhea, gynecomastia, menstrual disorders or erectile dysfunction. Psychiatric disorders Common: drowsiness/sleepiness, insomnia, agitation, impassivity. Nervous system disorders Common: Dizziness/vertigo, headache. 5
6 Parkinsonism and symptoms related symptoms: tremor, hypertonia, hypokinesia, hypersalivation. These symptoms are generally reversible upon administration of antiparkinsonian medicines. Uncommon: Akathisia, dystonia (spasm, torticollis, oculogyric crisis, and trismus). These symptoms are generally reversible upon administration of antiparkinsonian medicines. Rare: Acute dyskinesia. This symptom is generally reversible upon administration of antiparkinsonian medicines. Reproductive system and breast disorders Uncommon: Galactorrhea, amenorrhea, breast enlargement, breast pain, impotence. General disorders and administration site conditions Common: Asthenia/fatigue Uncommon: Weight increase Post marketing data In addition to the above, cases of the following adverse reactions have been reported (spontaneous reporting only). Nervous system disorders Not known: Tardive dyskinesia (characterized by rhythmic, involuntary movements primarily of the tongue and/ or the face) have been reported, as with all neuroleptics, after a neuroleptic administration of more than 3 months. Antiparkinson treatment is ineffective, and it may even lead to aggravation of the symptoms. As in case of all antipsychotic agents, neuroleptic malignant syndrome may occur (see section 4.4), that is a complication with a potentially fatal outcome. Cardiac disorders Not known: QT interval prolongation, ventricular arrhythmias such as torsades de pointes, ventricular tachycardia, which may result in ventricular fibrillation or cardiac arrest and sudden death (see section 4.4). Vascular disorders Not known: Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs. Hypotension, usually orthostatic. Pregnancy, puerperium and perinatal conditions Not known: Drug withdrawal syndrome neonatal (see 4.6). 4.9 Overdose Signs and symptoms Experience regarding the overdose of tiapride is limited. Drowsiness, sedation, coma, hypotension and extrapyramidal symptoms may be observed. Treatment Hemodialysis should not be used in overdose to remove the active substance, because tiapride is moderately dialysed. There is no specific antidote to tiapride. Appropriate supportive measures (monitoring vital and cardiac functions) should therefore be instituted. In case of severe extrapyramidal symptoms, anticholinergic medicines should be administered. 6
7 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Benzamide-antipsychotics ATC code: NO5AL3 Tiapride is an atypical neuroleptic which exhibits selectivity in in-vitro studies for D2 and D3 dopamine subtype receptors without any affinity for subtype receptors of the principal central neurotransmitters (including serotonin, noradrenaline and histamine). These properties have been confirmed in neurochemical and behavioural studies in which antidopaminergic properties have been demonstrated in the absence of sedation, catalepsy and cognitive impairment. 5.2 Pharmacokinetic properties Tiapride is rapidly absorbed. Maximal concentration of the active substance are reached as early as within one hour. The absolute bioavailability of the tablets is 80%. Tiapride is mostly eliminated in the first 24 hour urine. Tiapride is mainly eliminated as the parent compound, although two metabolites have been identified. These are the N-oxide and the N-monodesethyl derivatives of the active substance. The elimination half-life is about 3 hours. 5.3 Preclinical safety data An increased incidence of breast tumours was observed in rats. This was probably due to hyperprolactinaemia as a consequence of the pharmacological action of the substance. This is probably a species-specific effect and does not constitute any particular risk to humans in therapeutic use. Other abnormalities seen in experimental animals were associated with the known pharmacological action. In studies on reproductive toxicity no signs of teratogenicity were observed, however, embryotoxic effects occurred. In a study on peri-postnatal toxicity toxic effects in the offspring were seen following high doses. A tiapride-induced reduced fertility was observed in rats due to a suppression of the estrous cycle in females and a reduced libido in males. These effects are related to the pharmacological effect of tiapride on prolactin secretion. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Mannitol (E421) Microcrystalline cellulose (E460) Magnesium stearate (E470b) Povidone K30 (E1201) Silica colloidal anhydrous (E551) 6.2 Incompatibilities 7
8 Not applicable. 6.3 Shelf life 3 years 6.4 Special precautions for storage This medicinal product does not require any special storage conditions. 6.5 Nature and content of containers PVC/Aluminium blister pack Pack of 10 tablets Pack of 20 tablets Pack of 50 tablets Pack of 60 tablets Pack of 100 tablets Hospital pack: 500 (10 x 50 tablets) Not all pack sizes may be marketed. 6.6 Special precautions for disposal No special requirements. 7. MARKETING AUTHORISATION HOLDER 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION 10. DATE OF REVISION OF THE TEXT 8
Core Safety Profile. Date of FAR:
Core Safety Profile Active substance: Tiapride Pharmaceutical form(s)/strength: 25, 50 and 100 mg tablets Oral solution 15.3 g/100 ml (drops) Injectable solution 100 mg/2 ml Granules 10% P - RMS: FR/H/PSUR/0023/001
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationCIZOREST Tablets (Amisulpride)
Published on: 2 Dec 2015 CIZOREST Tablets (Amisulpride) Composition CIZOREST 50mg Tablets Each film-coated tablet contains: Amisulpride..50 mg CIZOREST 100mg Tablets Each film-coated tablet contains: Amisulpride..100
More informationSOLIAN TABLETS 100mg and 400mg Prescribing Information
SOLIAN TABLETS 100mg and 400mg Prescribing Information 1. NAME OF THE MEDICINAL PRODUCT Solian 100 mg, scored tablets Solian 400 mg, scored tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Amisulpride
More informationSUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine
SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine 1. DENOMINATION HYPERIUM 1 mg, tablets 2. COMPOSITION Rilmenidine (I.N.N.) dihydrogenphosphate.1.544 mg amount equivalent to rilmenidine
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dolmatil 400mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 400mg of the active substance sulpiride. Also contains
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Solian Solution, 100mg/ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Amisulpride 100 mg/ml For excipients, see 6.1. 3 PHARMACEUTICAL FORM
More information0BCore Safety Profile
0BCore Safety Profile Active substance: Chlorpromazine Pharmaceutical form(s)/strength: 10mg, 25mg, 50mg and 100mg fim-coated or uncoated tablets 5mg/ml syrup, 10mg/ml and 20mg/ml suspension forte, 40mg/ml
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT SOLIAN 50 SOLIAN 100 SOLIAN 200 SOLIAN 400 Solian Solution, 100mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient: Amisulpride
More informationNew Zealand Data Sheet APO-AMISULPRIDE
New Zealand Data Sheet APO-AMISULPRIDE Presentation APO-AMISULPRIDE 50mg are white to off-white, 6.0mm, round, biconvex tablets, with break line on one side. APO-AMISULPRIDE 100mg are white to off-white,
More informationAmipride PRODUCT INFORMATION. Name of the medicine. Description. Pharmacology
Amipride PRODUCT INFORMATION Name of the medicine Amisulpride. The chemical name for amisulpride is -amino-n-[[(rs)--ethylpyrrolidin-- yl]methyl]--(ethylsulphonyl)--methoxybenzamide. Its structural formula
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationAPO-Amisulpride tablets. (R, S)-4-Amino-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenxamide
APO-Amisulpride tablets NAME OF THE MEDICINE Amisulpride. Chemical Name: (R, S)-4-Amino-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenxamide Structural Formula: Molecular Formula: C 17
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationInjection Colourless isotonic injection solution 25 mg per ml levomepromazine hydrochloride in ampoules of 1 ml.
NAME OF THE MEDICINE Levomepromazine hydrochloride 25mg/mL injection. PRESENTATION Injection Colourless isotonic injection solution 25 mg per ml levomepromazine hydrochloride in ampoules of 1 ml. USES
More informationSUMMARY OF PRODUCTS CHARACTERISTICS
יש להוסיף: "פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר" Version 13.0 August 2010 Based on French SPC November 2009 (includes GLU no. 4) SUMMARY OF PRODUCTS CHARACTERISTICS 1. NAME OF THE MEDICINAL
More informationDATASHEET. SOLIAN TABLETS and SOLUTION NAME OF THE MEDICINE DESCRIPTION. SOLIAN 50 SOLIAN 100 SOLIAN 200 SOLIAN 400 SOLIAN SOLUTION 100mg/mL
NAME OF THE MEDICINE SOLIAN 50 SOLIAN 100 SOLIAN 200 SOLIAN 400 SOLIAN SOLUTION 100mg/mL Non-proprietary Name Amisulpride Chemical Structure DATASHEET SOLIAN TABLETS and SOLUTION Chemical Name: (R, S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-
More informationChemical name : (R, S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2- methoxybenzamide
Sulprix Amisulpride PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient : Amisulpride Chemical name : (R, S)--Amino-N-[(-ethyl--pyrrolidinyl)methyl]-5-ethylsulfonyl-- methoxybenzamide Structural
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationPRAMIN PRODUCT INFORMATION
PRAMIN PRODUCT INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Pramin Tablets Pramin Injection Pramin Suppositories 5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pramin Tablets: Each tablet contains: Metoclopramide
More informationEGLONYL FORTE 200mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER EGLONYL FORTE 200mg tablets SULPIRIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationAPO-Amisulpride tablets. (R, S)-4-Amino-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenxamide
APO-Amisulpride tablets NAME OF THE MEDICINE Amisulpride. Chemical Name: (R, S)-4-Amino-N-[1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenxamide Structural Formula: Molecular Formula: C17H27N3O4S
More informationSIFROL Composition Properties Indication
SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationPRODUCT INFORMATION. (R, S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2- methoxybenzamide
NAME OF THE MEDICINE AMISULPRIDE 5 WINTHROP PRODUCT INFORMATION AMISULPRIDE WINTHROP TABLETS AND SOLUTION AMISULPRIDE WINTHROP AMISULPRIDE WINTHROP AMISULPRIDE WINTHROP AMISULPRIDE WINTHROP SOLUTION mg/ml
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each ml solution for injection contains phenylephrine hydrochloride corresponding to 0.1 mg phenylephrine.
1. NAME OF THE MEDICINAL PRODUCT Fenylefrin Abcur 0.05 mg/ml, solution for injection Fenylefrin Abcur 0.1 mg/ml, solution for injection SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE
More informationINSTRUCTION for medical use DOMRID SR
APPROVED Order of the Ministry of Health of Ukraine 15.09.2016 973 Registration certificate UA/8976/03/01 INSTRUCTION for medical use DOMRID SR Composition: active substance: domperidone maleate; 1 tablet
More informationDATASHEET PIPORTIL NAME OF THE MEDICINE USES INDICATIONS CONTRAINDICATIONS. Pipothiazine palmitate 50 mg/ml injection
DATASHEET PIPORTIL NAME OF THE MEDICINE Pipothiazine palmitate 50 mg/ml injection PRESENTATION Injection (in sesame oil) 50 mg/ml; straw-coloured viscous liquid. USES Actions Pipothiazine palmitate is
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationPRODUCT INFORMATION. (R, S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2- methoxybenzamide
NAME OF THE MEDICINE AMISULPRIDE 5 WINTHROP PRODUCT INFORMATION AMISULPRIDE WINTHROP TABLETS AND SOLUTION AMISULPRIDE WINTHROP AMISULPRIDE WINTHROP AMISULPRIDE WINTHROP AMISULPRIDE WINTHROP SOLUTION mg/ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationPRODUCT INFORMATION. Neuroleptic of the benzamide class (R, S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2- methoxybenzamide N H
NAME OF THE DRUG SOLIAN SOLIAN SOLIAN SOLIAN Solution mg/ml Active Ingredient: Class: Chemical Name: PRODUCT INFORMATION SOLIAN TABLETS and SOLUTION Amisulpride Molecular Weight: 69.8 Molecular Formula:
More informationPRODUCT INFORMATION. (R, S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2- methoxybenzamide
NAME OF THE MEDICINE SOLIAN 5 SOLIAN SOLIAN SOLIAN SOLIAN SOLUTION mg/ml Australian Approved Name Amisulpride Chemical Structure PRODUCT INFORMATION SOLIAN TABLETS and SOLUTION Chemical Name: Molecular
More informationExcipient with known effect: One tablet contains mg lactose monohydrate.
1. NAME OF THE MEDICINAL PRODUCT Bicacta 50 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 50 mg bicalutamide. Excipient with known effect: One tablet contains
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationPackage leaflet: Information for the patient. Amisulpride 50 mg, 100 mg, 200 mg tablets Amisulpride 400 mg film-coated tablets Amisulpride
Package leaflet: Information for the patient Amisulpride 50 mg, 100 mg, 200 mg tablets Amisulpride 400 mg film-coated tablets Amisulpride Read all of this leaflet carefully before you start taking this
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationAUSTRALIAN PRODUCT INFORMATION SOLIAN (AMISULPRIDE) TABLETS AND SOLUTION 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION SOLIAN (AMISULPRIDE) TABLETS AND SOLUTION NAME OF THE MEDICINE Amisulpride QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets SOLIAN Tablets contain amisulpride (5 mg, mg,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationNAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon-A contains naphazoline hydrochloride
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklo-f 500 mg film coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains tranexamic acid 500 mg For the full
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationDomperidon Betapharm 10 mg tablets. Summary of Product Characteristics. 1:(to be changed into local product name in each CMS after day 90)
1. NAME OF THE MEDICINAL PRODUCT Domperidone Betapharm10 mg, tablets 1 Summary of Product Characteristics 1:(to be changed into local product name in each CMS after day 90) 2. QUALITATIVE AND QUANTITATIVE
More informationCore Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg
Core Safety Profile chlorprothixene /Truxal tablets 5 mg, 15 mg, 25 mg, 50 mg, 100 mg 4.2 Posology and method of administration Children and adolescents Chlorprothixene is not recommended for use in children
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationPackage leaflet: Information for the user. Tetrabenazine 25 mg tablets. tetrabenazine
Package leaflet: Information for the user Tetrabenazine 25 mg tablets tetrabenazine Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationDo not take Product name: If you are allergic to levosulpiride or any of the other ingredients of this medicine (listed in section 6).
Package leaflet: Information for the patient Product name 25 mg tablets Levosulpiride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT YOCON-GLENWOOD Tablets 5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 5 mg yohimbine hydrochloride. For a full list of excipients, see section 6.1. 3
More informationNew Zealand Data sheet
1. PRODUCT NAME (strength pharmaceutical form) Buccastem 3mg Buccal Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Prochlorperazine maleate 3 mg Each buccal
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:
Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT HYPERIUM 1 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Rilmenidine dihydrogen phosphate... 1.544 mg Corresponding
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Prometazin Actavis 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 25 mg of promethazine
More informationSIBELIUM Capsules Janssen
SIBELIUM Capsules Janssen NAME OF THE MEDICINAL PRODUCT Trade name SIBELIUM International Non-Proprietary Name (Modified) (rinnm) flunarizine hydrochloride QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationPackage leaflet: Information for the user. Tardiben 25 mg tablets. Tetrabenazine
PACKAGE LEAFLET 1 Package leaflet: Information for the user Tardiben 25 mg tablets Tetrabenazine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationC O N F I D E N T I A L
1. NAME OF THE MEDICINAL PRODUCT Lacinet 10 mg, orodispergeerbare tabletten Lacinet 20 mg, orodispergeerbare tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 10
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationNATRILIX SR SERVIER - LES LABORATOIRES SERVIER INDUSTRIE
08-15 NATRILIX SR SERVIER - LES LABORATOIRES SERVIER INDUSTRIE 1. NAME OF THE MEDICINAL PRODUCT NATRILIX SR, sustained-release film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Indapamide
More informationPRODUCT INFORMATION ANAGRAINE. Each ANAGRAINE tablet contains 5 mg metoclopramide and 500 mg paracetamol.
PRODUCT INFORMATION ANAGRAINE COMPOSITION Each ANAGRAINE tablet contains 5 mg metoclopramide and 500 mg paracetamol. ACTIONS Metoclopramide stimulates gastrointestinal tract motility and accelerates gastric
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More informationNOZINAN 25 mg film-coated tablets / 100 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NOZINAN 25 mg film-coated tablets / 100 mg film-coated tablets LEVOMEPROMAZINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cardide SR 1.5 mg Prolonged-Release Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Prolonged-Release Tablet contains 1.5 mg
More informationElements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationSummary of Product Characteristics
TRANSLATION FROM LATVIAN Summary of Product Characteristics State Agency of Medicines, Director I.Adoviča /signature/ Registered No.10843-300708 1. NAME OF THE MEDICINAL PRODUCT ADAPTOL 500 mg Tabletes
More informationPART IB : SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GUTRON QUALITATIVE AND QUANTITATIVE COMPOSITION
1 PART IB : SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GUTRON 2.5 2. QUALITATIVE AND QUANTITATIVE COMPOSITION For each tablet 2,5 mg midodrine hydrochloride. For excipients see
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report
More informationMetoclopramide hydrochloride mg (Quantity corresponding to anhydrous metoclopramide hydrochloride) mg
Name Primperan 10 mg Breakable tablets Metoclopramide hydrochloride Before taking this medicine Carefully read the entirety of this leaflet before taking this medicine. It contains important information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Miramel 0.088 mg, 0.18 mg, and 0.7 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Miramel 0.088 mg tablets: One tablet contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ketosteril film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: (RS)-3-methyl-2-oxovaleric
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ondansetron Aristo 4 mg film-coated tablets Ondansetron Aristo 8 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationPhysiotens 0.2 mg Abbott
10-14 Physiotens 0.2 mg Abbott Film-coated tablets 0.2 mg moxonidine Physiotens 0.2 mg tablets are round, convex, light pink, film-coated tablets with the stamp «0.2» on one face. Each tablet contains
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationAUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
More informationVALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics
Sandoz Business use only Page 1 of 5 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Valeriaan Sandoz omhulde tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains
More information